Insights

Biotechnology Innovation4D Molecular Therapeutics is revolutionizing genetic medicine, offering innovative products with the potential to treat large market and rare diseases. This presents a sales opportunity for targeting healthcare providers looking for cutting-edge therapeutic solutions.

Pipeline DiversityWith five product candidates in clinical trials across seven patient populations, 4D Molecular Therapeutics has a diverse genetic medicine pipeline. Sales teams can leverage this broad portfolio to engage with a wide range of healthcare institutions and explore partnership opportunities.

Public VisibilityAs a Nasdaq-listed company, 4D Molecular Therapeutics has garnered public attention through events, conferences, and regulatory updates, enhancing its visibility in the biotechnology sector. Leveraging this exposure can help sales representatives establish credibility and attract investor interest.

Financial HealthWith reported revenue between $10M to $50M and $300M in funding, 4D Molecular Therapeutics demonstrates strong financial stability. This financial health can be a compelling selling point for engaging potential investors or partners looking for long-term collaborations with a secure entity.

Competitive LandscapeAmong similar companies in the biotechnology space, 4D Molecular Therapeutics stands out with its unique vector discovery platform and product development engine. Highlighting these competitive advantages can differentiate the company in sales pitches and attract collaborations from partners seeking innovative genetic medicine solutions.

4D Molecular Therapeutics Tech Stack

4D Molecular Therapeutics uses 8 technology products and services including Power BI, NetSuite, PyTorch, and more. Explore 4D Molecular Therapeutics's tech stack below.

  • Power BI
    Business Intelligence
  • NetSuite
    E-commerce
  • PyTorch
    Machine Learning
  • Microsoft
    Miscellaneous
  • Glassdoor
    Online Review Management
  • WP Engine
    Platform As A Service
  • Linux
    Programming Languages
  • Greenhouse
    Recruitment Marketing

Media & News

4D Molecular Therapeutics's Email Address Formats

4D Molecular Therapeutics uses at least 1 format(s):
4D Molecular Therapeutics Email FormatsExamplePercentage
FLast@4dmoleculartherapeutics.comJDoe@4dmoleculartherapeutics.com
83%
First.Last@4dmoleculartherapeutics.comJohn.Doe@4dmoleculartherapeutics.com
15%
Last.First@4dmoleculartherapeutics.comDoe.John@4dmoleculartherapeutics.com
2%

Frequently Asked Questions

Where is 4D Molecular Therapeutics's headquarters located?

Minus sign iconPlus sign icon
4D Molecular Therapeutics's main headquarters is located at 5858 Horton St 455 Emeryville, California 94608 US. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is 4D Molecular Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact 4D Molecular Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is 4D Molecular Therapeutics's stock symbol?

Minus sign iconPlus sign icon
4D Molecular Therapeutics is a publicly traded company; the company's stock symbol is FDMT.

What is 4D Molecular Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
4D Molecular Therapeutics's official website is 4dmoleculartherapeutics.com and has social profiles on LinkedIn.

How much revenue does 4D Molecular Therapeutics generate?

Minus sign iconPlus sign icon
As of April 2025, 4D Molecular Therapeutics's annual revenue reached $35M.

What is 4D Molecular Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
4D Molecular Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does 4D Molecular Therapeutics have currently?

Minus sign iconPlus sign icon
As of April 2025, 4D Molecular Therapeutics has approximately 239 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Commercial Officer: C. S.Chief Financial And Business Officer: U. M.Chief Medical Officer: R. K.. Explore 4D Molecular Therapeutics's employee directory with LeadIQ.

What industry does 4D Molecular Therapeutics belong to?

Minus sign iconPlus sign icon
4D Molecular Therapeutics operates in the Biotechnology Research industry.

What technology does 4D Molecular Therapeutics use?

Minus sign iconPlus sign icon
4D Molecular Therapeutics's tech stack includes Power BINetSuitePyTorchMicrosoftGlassdoorWP EngineLinuxGreenhouse.

What is 4D Molecular Therapeutics's email format?

Minus sign iconPlus sign icon
4D Molecular Therapeutics's email format typically follows the pattern of . Find more 4D Molecular Therapeutics email formats with LeadIQ.

How much funding has 4D Molecular Therapeutics raised to date?

Minus sign iconPlus sign icon
As of April 2025, 4D Molecular Therapeutics has raised $300M in funding. The last funding round occurred on Feb 06, 2024 for $300M.

When was 4D Molecular Therapeutics founded?

Minus sign iconPlus sign icon
4D Molecular Therapeutics was founded in 2013.
4D Molecular Therapeutics

4D Molecular Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: 
-	Dare to Cure
-	Break Boundaries 
-	Beyond Yourself 
-	Prepare & Execute Relentlessly 

Join us in creating the future of genetic medicine.

Section iconCompany Overview

Headquarters
5858 Horton St 455 Emeryville, California 94608 US
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
FDMT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
201-500

Section iconFunding & Financials

  • $300M

    4D Molecular Therapeutics has raised a total of $300M of funding over 6 rounds. Their latest funding round was raised on Feb 06, 2024 in the amount of $300M.

  • $10M$50M

    4D Molecular Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $300M

    4D Molecular Therapeutics has raised a total of $300M of funding over 6 rounds. Their latest funding round was raised on Feb 06, 2024 in the amount of $300M.

  • $10M$50M

    4D Molecular Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.